Trevi Therapeutics Unveils Exciting Research at CHEST 2025 Meeting

Trevi Therapeutics to Present Key Findings at CHEST 2025

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical firm, is excited to announce its participation in the upcoming CHEST 2025 Annual Meeting, held from October 19-22 in Chicago, Illinois. This year, Trevi will present vital findings from two pivotal studies focusing on its investigational drug, nalbuphine extended-release (ER), aimed at addressing chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and other chronic conditions.

Oral Presentation Highlights

Professor Philip Molyneaux is set to deliver an oral presentation detailing the efficacy and safety outcomes observed in the Phase 2b CORAL trial. This significant study tested nalbuphine ER's effectiveness against chronic cough in IPF patients. The CORAL trial was designed as a double-blind, randomized, placebo-controlled study, involving 165 patients who were divided into several groups receiving varying doses of nalbuphine ER or placebo over an extended period of six weeks. The main goal was to measure changes in 24-hour cough frequency using objective monitoring, comparing results from the active treatment groups to those receiving placebo. The outcomes of this trial could potentially lead to a breakthrough in the management of chronic cough associated with IPF, offering hope to a patient population that has faced a dire lack of effective therapies.

Poster Presentation Overview

In parallel, Associate Professor Imran Satia will showcase patient-reported outcomes from the Phase 2a RIVER trial in a poster session. The RIVER trial examined the perception of cough-related symptoms and overall patient wellbeing among individuals with refractory chronic cough—another demanding condition with insufficient current treatment options. This randomized, placebo-controlled trial involved two treatment periods separated by a washout phase, further illuminating the therapeutic value of nalbuphine ER in alleviating chronic cough in patients who have not responded adequately to standard therapies.

The Importance of Addressing Chronic Cough

Chronic cough is a serious and often debilitating condition, especially for patients with IPF and non-IPF interstitial lung diseases. Approximately 150,000 individuals in the U.S. are diagnosed with IPF, and a staggering two-thirds experience chronic cough, which can significantly diminish quality of life. With existing medications often failing to provide relief, the need for an innovative treatment like nalbuphine ER cannot be overstated. This drug works differently than traditional cough suppressants by engaging opioid receptors that influence cough reflex pathways, targeting both central and peripheral mechanisms.

Refractory chronic cough affects around 2-3 million people in the United States, leaving many without FDA-approved solutions. Trevi Therapeutics’ focused efforts aim to fill this critical gap in the medical market, potentially transforming the landscape for chronic cough management.

Looking Forward

Trevi Therapeutics is enthusiastic about the critical feedback and insights it hopes to gain at CHEST 2025. The company is keen to engage with healthcare professionals, researchers, and stakeholders to discuss the future of chronic cough treatment and the potential commercialization of nalbuphine ER under the proposed trade name Haduvio. As regulatory evaluations continue, Trevi is committed to transparency and ongoing research that prioritizes patient health outcomes.

For updates, stay tuned to Trevi Therapeutics' official platforms, including their website and social media channels.

Contact and More Information

For further inquiries, please reach out to Trevi Therapeutics’ investor contact, Jonathan Carlson, at (203) 654-3286 or [email protected]. Media inquiries can be directed to Rosalia Scampoli at 914-815-1465 or [email protected].

As Trevi launches its exploration at CHEST 2025, the future looks promising for both the company and the patients looking for answers to their chronic cough challenges.